<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37248338</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Seeding the aggregation of TDP-43 requires post-fibrillization proteolytic cleavage.</ArticleTitle><Pagination><StartPage>983</StartPage><EndPage>996</EndPage><MedlinePgn>983-996</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-023-01341-4</ELocationID><Abstract><AbstractText>Despite the strong evidence linking the transactive response DNA-binding protein 43 (TDP-43) aggregation to the pathogenesis of frontotemporal lobar degeneration with TDP-43, amyotrophic lateral sclerosis and several neurodegenerative diseases, our knowledge of the sequence and structural determinants of its aggregation and neurotoxicity remains incomplete. Herein, we present a new method for producing recombinant full-length TDP-43 filaments that exhibit sequence and morphological features similar to those of brain-derived TDP-43 filaments. We show that TDP-43 filaments contain a &#x3b2;-sheet-rich helical amyloid core that is fully buried by the flanking structured domains of the protein. We demonstrate that the proteolytic cleavage of TDP-43 filaments and exposure of this amyloid core are necessary for propagating TDP-43 pathology and enhancing the seeding of brain-derived TDP-43 aggregates. Only TDP-43 filaments with exposed amyloid core efficiently seeded the aggregation of endogenous TDP-43 in cells. These findings suggest that inhibiting the enzymes mediating cleavage of TDP-43 aggregates represents a viable disease-modifying strategy to slow the progression of amyotrophic lateral sclerosis and other TDP-43 proteinopathies.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Senthil T</ForeName><Initials>ST</Initials><Identifier Source="ORCID">0000-0002-4322-3963</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nazarov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porta</LastName><ForeName>S&#xed;lvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research (CNDR), Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maharjan</LastName><ForeName>Niran</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cendrowska</LastName><ForeName>Urszula</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabani</LastName><ForeName>Malek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finamore</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research (CNDR), Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0003-3536-6902</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research (CNDR), Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashuel</LastName><ForeName>Hilal A</ForeName><Initials>HA</Initials><Identifier Source="ORCID">0000-0001-7682-8320</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, EPFL, Lausanne, Switzerland. hilal.lashuel@epfl.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>H.A.L. is the founder and chief scientific officer of ND BioSciences, Epalinges, Switzerland, a company that develops diagnostics and treatments for NDs based on platforms that reproduce the complexity and diversity of proteins implicated in NDs and their pathologies. H.A.L. has received funding from the industry to support research on neurodegenerative diseases, including from Merck Serono, AC Immune, UCB Idorsia and Abbvie. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37248338</ArticleId><ArticleId IdType="pmc">PMC10244175</ArticleId><ArticleId IdType="doi">10.1038/s41593-023-01341-4</ArticleId><ArticleId IdType="pii">10.1038/s41593-023-01341-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013;14:248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, et al. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2017;5:76. doi: 10.1186/s40478-017-0480-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0480-2</ArticleId><ArticleId IdType="pmc">PMC5658959</ArticleId><ArticleId IdType="pubmed">29078806</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, et al. Astrocytes and microglia as non-cell autonomous players in the pathogenesis of ALS. Exp. Neurobiol. 2016;25:233&#x2013;240. doi: 10.5607/en.2016.25.5.233.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2016.25.5.233</ArticleId><ArticleId IdType="pmc">PMC5081469</ArticleId><ArticleId IdType="pubmed">27790057</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD. Glial cells in amyotrophic lateral sclerosis. Exp. Neurol. 2014;262:111&#x2013;120. doi: 10.1016/j.expneurol.2014.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.05.015</ArticleId><ArticleId IdType="pmc">PMC4241182</ArticleId><ArticleId IdType="pubmed">24859452</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503&#x2013;1527. doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, et al. TDP-43 pathology in Alzheimer&#x2019;s disease, dementia with Lewy bodies and ageing. Brain Pathol. 2017;27:472&#x2013;479. doi: 10.1111/bpa.12424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12424</ArticleId><ArticleId IdType="pmc">PMC8029292</ArticleId><ArticleId IdType="pubmed">27495267</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukavsky PJ, et al. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat. Struct. Mol. Biol. 2013;20:1443&#x2013;1449. doi: 10.1038/nsmb.2698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2698</ArticleId><ArticleId IdType="pubmed">24240615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompe&#xe1;n M, et al. The TDP-43 N-terminal domain structure at high resolution. FEBS J. 2016;283:1242&#x2013;1260. doi: 10.1111/febs.13651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.13651</ArticleId><ArticleId IdType="pubmed">26756435</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat. Commun. 2017;8:45. doi: 10.1038/s41467-017-00062-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00062-0</ArticleId><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, et al. TDP-43 &#x3b1;-helical structure tunes liquid-liquid phase separation and function. Proc. Natl Acad. Sci. USA. 2020;117:5883&#x2013;5894. doi: 10.1073/pnas.1912055117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1912055117</ArticleId><ArticleId IdType="pmc">PMC7084079</ArticleId><ArticleId IdType="pubmed">32132204</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem. 2005;280:37572&#x2013;37584. doi: 10.1074/jbc.M505557200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505557200</ArticleId><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L, Wei Y, Lu Y, Song J. ALS-causing mutations significantly perturb the self-assembly and interaction with nucleic acid of the intrinsically disordered prion-like domain of TDP-43. PLoS Biol. 2016;14:e1002338. doi: 10.1371/journal.pbio.1002338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1002338</ArticleId><ArticleId IdType="pmc">PMC4703307</ArticleId><ArticleId IdType="pubmed">26735904</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AK, et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J. Am. Chem. Soc. 2010;132:1186&#x2013;1187. doi: 10.1021/ja9066207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja9066207</ArticleId><ArticleId IdType="pubmed">20055380</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, L. &amp; Shorter, J. Biology and pathobiology of TDP-43 and emergent therapeutic strategies. Cold Spring Harb. Perspect. Med.10.1101/cshperspect.a024554 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5580514</ArticleId><ArticleId IdType="pubmed">27920024</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional significance of TDP-43 mutations in disease. Adv. Genet. 2015;91:1&#x2013;53. doi: 10.1016/bs.adgen.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.adgen.2015.07.001</ArticleId><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH, et al. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol. 2013;125:463&#x2013;465. doi: 10.1007/s00401-013-1089-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1089-6</ArticleId><ArticleId IdType="pmc">PMC3593646</ArticleId><ArticleId IdType="pubmed">23378033</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, et al. TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol. 2013;125:121&#x2013;131. doi: 10.1007/s00401-012-1055-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1055-8</ArticleId><ArticleId IdType="pmc">PMC3536927</ArticleId><ArticleId IdType="pubmed">23124365</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 2007;171:227&#x2013;240. doi: 10.2353/ajpath.2007.070182.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070182</ArticleId><ArticleId IdType="pmc">PMC1941578</ArticleId><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Dickson DW. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 2008;116:205&#x2013;213. doi: 10.1007/s00401-008-0408-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0408-9</ArticleId><ArticleId IdType="pmc">PMC2706695</ArticleId><ArticleId IdType="pubmed">18607609</ArticleId></ArticleIdList></Reference><Reference><Citation>Arseni D, et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601:139&#x2013;143. doi: 10.1038/s41586-021-04199-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04199-3</ArticleId><ArticleId IdType="pmc">PMC7612255</ArticleId><ArticleId IdType="pubmed">34880495</ArticleId></ArticleIdList></Reference><Reference><Citation>Reif A, Chiki A, Ricci J, Lashuel HA. Generation of native, untagged huntingtin exon1 monomer and fibrils using a SUMO fusion strategy. J. Vis. Exp. 2018 doi: 10.3791/57506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/57506</ArticleId><ArticleId IdType="pmc">PMC6102005</ArticleId><ArticleId IdType="pubmed">30010666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tileva M, Krachmarova E, Ivanov I, Maskos K, Nacheva G. Production of aggregation prone human interferon gamma and its mutant in highly soluble and biologically active form by SUMO fusion technology. Protein Expr. Purif. 2016;117:26&#x2013;34. doi: 10.1016/j.pep.2015.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pep.2015.09.022</ArticleId><ArticleId IdType="pubmed">26407523</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson JR, et al. Generation of alpha-synuclein preformed fibrils from monomers and use in vivo. J. Vis. Exp. 2019 doi: 10.3791/59758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/59758</ArticleId><ArticleId IdType="pubmed">31205308</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickhardt M, et al. Screening for inhibitors of tau polymerization. Curr. Alzheimer Res. 2005;2:219&#x2013;226. doi: 10.2174/1567205053585891.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205053585891</ArticleId><ArticleId IdType="pubmed">15974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gremer L, et al. Fibril structure of amyloid-&#x3b2;1&#x2013;42 by cryo-electron microscopy. Science. 2017;358:116&#x2013;119. doi: 10.1126/science.aao2825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao2825</ArticleId><ArticleId IdType="pmc">PMC6080689</ArticleId><ArticleId IdType="pubmed">28882996</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmer M, et al. Cryo-EM structure and polymorphism of A&#x3b2; amyloid fibrils purified from Alzheimer&#x2019;s brain tissue. Nat. Commun. 2019;10:4760. doi: 10.1038/s41467-019-12683-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12683-8</ArticleId><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="pubmed">31664019</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther RA, Daniel SE, Goedert M. Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson&#x2019;s disease brain. Neurosci. Lett. 2000;292:128&#x2013;130. doi: 10.1016/S0304-3940(00)01440-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01440-3</ArticleId><ArticleId IdType="pubmed">10998565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cendrowska U, et al. Unraveling the complexity of amyloid polymorphism using gold nanoparticles and cryo-EM. Proc. Natl Acad. Sci. USA. 2020;117:6866&#x2013;6874. doi: 10.1073/pnas.1916176117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1916176117</ArticleId><ArticleId IdType="pmc">PMC7104366</ArticleId><ArticleId IdType="pubmed">32161130</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazarov S, Chiki A, Boudeffa D, Lashuel HA. Structural basis of huntingtin fibril polymorphism revealed by cryogenic electron microscopy of exon 1 HTT fibrils. J. Am. Chem. Soc. 2022;144:10723&#x2013;10735. doi: 10.1021/jacs.2c00509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.2c00509</ArticleId><ArticleId IdType="pubmed">35679155</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat. Commun. 2018;9:4220. doi: 10.1038/s41467-018-06548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06548-9</ArticleId><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, et al. Distinct brain-derived TDP-43 strains from FTLD-TDP subtypes induce diverse morphological TDP-43 aggregates and spreading patterns in vitro and in vivo. Neuropathol. Appl Neurobiol. 2021;47:1033&#x2013;1049. doi: 10.1111/nan.12732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12732</ArticleId><ArticleId IdType="pmc">PMC8578586</ArticleId><ArticleId IdType="pubmed">33971027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M, et al. Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature. 2022;605:310&#x2013;314. doi: 10.1038/s41586-022-04650-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04650-z</ArticleId><ArticleId IdType="pmc">PMC9095482</ArticleId><ArticleId IdType="pubmed">35344985</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang YX, et al. Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43. Nature. 2022;605:304&#x2013;309. doi: 10.1038/s41586-022-04670-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04670-9</ArticleId><ArticleId IdType="pmc">PMC9844993</ArticleId><ArticleId IdType="pubmed">35344984</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, et al. Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell. 2022;185:1346&#x2013;1355. doi: 10.1016/j.cell.2022.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.02.026</ArticleId><ArticleId IdType="pmc">PMC9018563</ArticleId><ArticleId IdType="pubmed">35247328</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, et al. Generic amyloid fibrillation of TMEM106B in patient with Parkinson&#x2019;s disease dementia and normal elders. Cell Res. 2022;32:585&#x2013;588. doi: 10.1038/s41422-022-00665-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00665-3</ArticleId><ArticleId IdType="pmc">PMC9160068</ArticleId><ArticleId IdType="pubmed">35477998</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferri&#xe8;re F, et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat. Neurosci. 2019;22:65&#x2013;77. doi: 10.1038/s41593-018-0294-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0294-y</ArticleId><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4:124&#x2013;134. doi: 10.1016/j.celrep.2013.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, et al. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol. 2008;116:193&#x2013;203. doi: 10.1007/s00401-008-0396-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0396-9</ArticleId><ArticleId IdType="pubmed">18560845</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahul-Mellier, A. -L. et al. The making of a Lewy body: the role of &#x3b1;-synuclein post-fibrillization modifications in regulating the formation and the maturation of pathological inclusions. Preprint at bioRxiv10.1101/500058 (2018).</Citation></Reference><Reference><Citation>Moors TE, et al. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson&#x2019;s disease brain as revealed by multicolor STED microscopy. Acta Neuropathol. 2021;142:423&#x2013;448. doi: 10.1007/s00401-021-02329-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02329-9</ArticleId><ArticleId IdType="pmc">PMC8357756</ArticleId><ArticleId IdType="pubmed">34115198</ArticleId></ArticleIdList></Reference><Reference><Citation>Balana, A. T. et al. O-GlcNAc modification forces the formation of an &#x3b1;-Synuclein amyloid-strain with notably diminished seeding activity and pathology. Preprint at bioRxiv10.1101/2023.03.07.531573 (2023).</Citation></Reference><Reference><Citation>Donzelli, S. et al. Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo. Preprint at bioRxiv10.1101/2023.03.24.534149 (2023).</Citation></Reference><Reference><Citation>Josephs KA, et al. TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127:811&#x2013;824. doi: 10.1007/s00401-014-1269-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1269-z</ArticleId><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284&#x2013;294. doi: 10.1016/j.brainres.2007.09.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.048</ArticleId><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body-related diseases. Acta Neuropathol. 2007;114:221&#x2013;229. doi: 10.1007/s00401-007-0261-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0261-2</ArticleId><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149. doi: 10.1007/s00401-008-0477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessner D, Chambers M, Burke R, Agus D, Mallick P. ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics. 2008;24:2534&#x2013;2536. doi: 10.1093/bioinformatics/btn323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btn323</ArticleId><ArticleId IdType="pmc">PMC2732273</ArticleId><ArticleId IdType="pubmed">18606607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornson RD, et al. X!!Tandem, an improved method for running X!tandem in parallel on collections of commodity computers. J. Proteome Res. 2008;7:293&#x2013;299. doi: 10.1021/pr0701198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr0701198</ArticleId><ArticleId IdType="pmc">PMC3863625</ArticleId><ArticleId IdType="pubmed">17902638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggeri FS, et al. Nanoscale studies link amyloid maturity with polyglutamine diseases onset. Sci. Rep. 2016;6:31155. doi: 10.1038/srep31155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep31155</ArticleId><ArticleId IdType="pmc">PMC4976327</ArticleId><ArticleId IdType="pubmed">27499269</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, et al. A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimers Dement. 2014;10:477&#x2013;484. doi: 10.1016/j.jalz.2013.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.06.003</ArticleId><ArticleId IdType="pmc">PMC3933464</ArticleId><ArticleId IdType="pubmed">23978324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife10.7554/eLife.42166 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. Amyloid structure determination in RELION-3.1. Acta Crystallogr D. Struct. Biol. 2020;76:94&#x2013;101. doi: 10.1107/S2059798319016577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2059798319016577</ArticleId><ArticleId IdType="pmc">PMC7008511</ArticleId><ArticleId IdType="pubmed">32038040</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G, et al. EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 2007;157:38&#x2013;46. doi: 10.1016/j.jsb.2006.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2006.05.009</ArticleId><ArticleId IdType="pubmed">16859925</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner T, et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Commun. Biol. 2019;2:218. doi: 10.1038/s42003-019-0437-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-019-0437-z</ArticleId><ArticleId IdType="pmc">PMC6584505</ArticleId><ArticleId IdType="pubmed">31240256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, Nakane T, Scheres SHW. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ. 2020;7:253&#x2013;267. doi: 10.1107/S2052252520000081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2052252520000081</ArticleId><ArticleId IdType="pmc">PMC7055373</ArticleId><ArticleId IdType="pubmed">32148853</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov, J., Nakane, T. &amp; Scheres, S. H. W. A Bayesian approach to beam-induced motion correction in Cryo-EM single-particle analysis. IUCrJ6, 5&#x2013;17 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr. 2010;66:486&#x2013;501. doi: 10.1107/S0907444910007493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910007493</ArticleId><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnley T, Palmer CM, Winn M. Recent developments in the CCP-EM software suite. Acta Crystallogr D. Struct. Biol. 2017;73:469&#x2013;477. doi: 10.1107/S2059798317007859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2059798317007859</ArticleId><ArticleId IdType="pmc">PMC5458488</ArticleId><ArticleId IdType="pubmed">28580908</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D. Biol. Crystallogr. 2010;66:213&#x2013;221. doi: 10.1107/S0907444909052925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909052925</ArticleId><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D. Biol. Crystallogr. 2010;66:12&#x2013;21. doi: 10.1107/S0907444909042073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909042073</ArticleId><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein Data Bank. Nat. Struct. Biol. 2003;10:980. doi: 10.1038/nsb1203-980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsb1203-980</ArticleId><ArticleId IdType="pubmed">14634627</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, et al. Semi-automated digital image analysis of Pick&#x2019;s disease and TDP-43 proteinopathy. J. Histochem. Cytochem. 2016;64:54&#x2013;66. doi: 10.1369/0022155415614303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/0022155415614303</ArticleId><ArticleId IdType="pmc">PMC4810792</ArticleId><ArticleId IdType="pubmed">26538548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar ST, et al. A NAC domain mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein and recapitulates its pathological diversity. Sci. Adv. 2022;8:eabn0044. doi: 10.1126/sciadv.abn0044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abn0044</ArticleId><ArticleId IdType="pmc">PMC9054026</ArticleId><ArticleId IdType="pubmed">35486726</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang YS, et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat. Commun. 2014;5:4824. doi: 10.1038/ncomms5824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5824</ArticleId><ArticleId IdType="pubmed">25215604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Boyer DR, Sawaya MR, Ge P, Eisenberg DS. Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nat. Struct. Mol. Biol. 2019;26:619&#x2013;627. doi: 10.1038/s41594-019-0248-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-019-0248-4</ArticleId><ArticleId IdType="pmc">PMC7047951</ArticleId><ArticleId IdType="pubmed">31235914</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Babinchak WM, Surewicz WK. Cryo-EM structure of amyloid fibrils formed by the entire low complexity domain of TDP-43. Nat. Commun. 2021;12:1620. doi: 10.1038/s41467-021-21912-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21912-y</ArticleId><ArticleId IdType="pmc">PMC7955110</ArticleId><ArticleId IdType="pubmed">33712624</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>